Global Information
회사소개 | 문의 | 비교리스트

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 : 파이프라인 리뷰

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 288828
페이지 정보 영문 45 Pages 배송안내
가격
US $ 2,000 ₩ 2,543,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,086,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,630,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 : 파이프라인 리뷰 Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 45 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

MRSA(메티실린 내성 황색포도상구균)에는 메티실린을 포함한 일부 항생물질에 대한 내성을 갖고 있기 때문에 살균이 어렵다는 특징이 있습니다. 또 MRSA는 때때로 병원과 의료기관에서의 치료 행위와 관련지을 수 있습니다. 주요 질병 소질에는 현재 입원중인 점, 침습성 의료기기를 사용하고 있는 점, 장기간에 걸쳐 입원하고 있는 점 등이 있습니다. 위생을 지킴으로서 세균 감염의 위험을 경감할 수 있습니다.

세계 각국에서의 원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계에 있는 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 : 파이프라인 제품 분석 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 기업에서 개발중인 치료제

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 대학/연구기관에서 연구중인 치료제

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 기업에서 개발중인 제품

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 대학/연구기관에서 연구중인 제품

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 치료제 개발에 참여하고 있는 기업

  • Destiny Pharma Limited
  • Galapagos NV
  • MGB Biopharma Limited
  • Syntiron LLC
  • Techulon, Inc.

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 최근의 파이프라인 동향

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 휴지 상태인 프로젝트

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 개발이 중지된 제품

원내감염형 MRSA(메티실린 내성 황색포도상구균) 감염증 파이프라인 제품 분석 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 16.07.12

List of Tables

List of Tables

  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Cesa Alliance SA, 2021
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Plc, 2021
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Ltd, 2021
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Sichuan Saizhuo Pharmaceutical Co Ltd, 2021
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon Inc, 2021
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Valevia UK Ltd, 2021
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, 2021
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections - Drugs In Development, 2021, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warm to the touch, fever, and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device, and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Unknown stages are 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development
  • Cesa Alliance SA
  • Destiny Pharma Plc
  • MGB Biopharma Ltd
  • Sichuan Saizhuo Pharmaceutical Co Ltd
  • Techulon Inc
  • Valevia UK Ltd
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Drug Profiles
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones
  • Featured News & Press Releases
  • Mar 22, 2018: Sichuan Saizhuo Pharmaceutical obtained the clinical approval for a new drug "Ristazolone Dry Suspension"
  • Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q